{"url_path":"/sec/okyo/10-k/2026/item-8","section_key":"item-8","section_title":"Item 8 FINANCIAL INFORMATION**","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1849296/0001493152-26-033847-index.html","accession_number":"0001493152-26-033847","cik":"0001849296","ticker":"OKYO","issuer_name":"OKYO Pharma Ltd","edgar_url":"https://www.sec.gov/Archives/edgar/data/1849296/0001493152-26-033847-index.html","primary_entity_key":"0001849296","primary_entity_name":"OKYO Pharma Ltd"},"word_count":134,"has_tables":true,"body_markdown":"**ITEM\n8: FINANCIAL INFORMATION**\n\n \n\n**A.\nConsolidated Statements and Other Financial Information**\n\n \n\nSee\n“Item 18. Financial Statements”.\n\n \n\n**Legal\nProceedings**\n\n \n\nExcept\nas disclosed in this paragraph, there are no governmental, legal or arbitration proceedings (including any such proceedings which are\npending or threatened of which the Company is aware), which may have, or have had during the 12 months prior to the date of this annual\nreport, a significant effect on the Company’s and/or our financial position or profitability. In addition to the proceedings set\nout in this section, the Company is not involved in other legal proceedings and claims in the ordinary course of business.\n\n \n\n**B.\nSignificant Changes**\n\n \n\nSee\nNote 25 of our consolidated financial statements at the end of this Annual Report for a description of the significant changes since\nMarch 31, 2025.\n\n \n\n71"}